Catabasis Pharmaceuticals Inc (CATB) is Reiterated by Wedbush to Outperform, Lowers Price Target to $ 17

Catabasis Pharmaceuticals Inc (CATB) was Reiterated by Wedbush to “Outperform” while Lowering the Price Target of the company shares to $ 17 from a previous price target of $27 . Wedbush advised their investors in a research report released on Jun 8, 2016.

Catabasis Pharmaceuticals Inc closed down -0.27 points or -3.79% at $6.85 with 22,622 shares getting traded on Tuesday. Post opening the session at $7.23, the shares hit an intraday low of $6.65 and an intraday high of $7.23 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

In a different news, on Jun 30, 2015, Jean George (director) purchased 258,776 shares at $12.00 per share price.

Catabasis Pharmaceuticals Inc. (Catabasis) is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery development and commercialization of therapeutics based on its safely metabolized and rationally targeted (SMART) linker technology platform. Its SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating various biological targets in one or more related disease pathways. Catabasis engineers bi-functional product candidates that are conjugates of two molecules or bioactives each with known pharmacological activity joined by one of its SMART linkers. Catabasis is also engaged in developing other product candidates for the treatment of lipid disorders. The Company’s product development pipeline includes three clinical-stage product candidates namely CAT-1004 CAT-2000 series including CAT-2054 and CAT-2003 and CAT-4001 and various programs in preclinical development.

Catabasis Pharmaceuticals Inc

Leave a Reply

Catabasis Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Catabasis Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.